EURO-B.O.S.S.: a European study on chemotherapy in bone-sarcoma patients aged over 40: outcome in primary high-grade osteosarcoma
Introduction:The EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) was the first prospective international study for patients 41-65 years old with high-grade bone sarcoma treated with an intensive chemotherapy regimen derived from protocols for younger patients with high-grade skeletal osteosarcom...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
Tumori journal
Year: 2017, Jahrgang: 104, Heft: 1, Pages: 30-36 |
| ISSN: | 2038-2529 |
| DOI: | 10.5301/tj.5000696 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.5301/tj.5000696
|
| Verfasserangaben: | Stefano Ferrari, Stefan S. Bielack, Sigbjørn Smeland, Alessandra Longhi, Gerlinde Egerer, Kirsten Sundby Hall, Davide Donati, Matthias Kevric, Otte Brosjö, Alessandro Comandone, Mathias Werner, Odd Monge, Emanuela Palmerini, Wolfgang E. Berdel, Bodil Bjerkehagen, Anna Paioli, Sylvie Lorenzen, Mikael Eriksson, Marco Gambarotti, Per-Ulf Tunn, Nina L. Jebsen, Marilena Cesari, Thekla von Kalle, Virginia Ferraresi, Rudolf Schwarz, Rossella Bertulli, Anne-Katrin Kasparek, Giovanni Grignani, Fatime Krasniqi, Benjamin Sorg, Stefanie Hecker-Nolting, Piero Picci, Peter Reichardt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580944124 | ||
| 003 | DE-627 | ||
| 005 | 20220815010702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180913r20182017xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5301/tj.5000696 |2 doi | |
| 035 | |a (DE-627)1580944124 | ||
| 035 | |a (DE-576)510944124 | ||
| 035 | |a (DE-599)BSZ510944124 | ||
| 035 | |a (OCoLC)1341018503 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ferrari, Stefano |d 1958- |e VerfasserIn |0 (DE-588)1090236905 |0 (DE-627)854078207 |0 (DE-576)460152785 |4 aut | |
| 245 | 1 | 0 | |a EURO-B.O.S.S. |b a European study on chemotherapy in bone-sarcoma patients aged over 40: outcome in primary high-grade osteosarcoma |c Stefano Ferrari, Stefan S. Bielack, Sigbjørn Smeland, Alessandra Longhi, Gerlinde Egerer, Kirsten Sundby Hall, Davide Donati, Matthias Kevric, Otte Brosjö, Alessandro Comandone, Mathias Werner, Odd Monge, Emanuela Palmerini, Wolfgang E. Berdel, Bodil Bjerkehagen, Anna Paioli, Sylvie Lorenzen, Mikael Eriksson, Marco Gambarotti, Per-Ulf Tunn, Nina L. Jebsen, Marilena Cesari, Thekla von Kalle, Virginia Ferraresi, Rudolf Schwarz, Rossella Bertulli, Anne-Katrin Kasparek, Giovanni Grignani, Fatime Krasniqi, Benjamin Sorg, Stefanie Hecker-Nolting, Piero Picci, Peter Reichardt |
| 264 | 1 | |c 2018 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: December 5, 2017 | ||
| 500 | |a Gesehen am 30.08.2019 | ||
| 520 | |a Introduction:The EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) was the first prospective international study for patients 41-65 years old with high-grade bone sarcoma treated with an intensive chemotherapy regimen derived from protocols for younger patients with high-grade skeletal osteosarcoma.Methods:Chemotherapy based on doxorubicin, cisplatin, ifosfamide, and methotrexate was suggested, but patients treated with other regimens at the investigators? choice were also eligible for the study.Results:The present report focuses on the subgroup of 218 patients with primary high-grade osteosarcoma. With a median follow-up of 47 months, the 5-year probability of overall survival (OS) was 66% in patients with localized disease and 22% in case of synchronous metastases. The 5-year OS in patients with localized disease was 29% in pelvic tumors, and 70% and 73% for extremity or craniofacial locations, respectively.In primary chemotherapy, tumor necrosis ≥90% was reported in 21% of the patients. There were no toxic deaths; however, hematological toxicity was considerable with 32% of patients experiencing 1 or more episodes of neutropenic fever. The incidence of nephrotoxicity and neurotoxicity (mainly peripheral) was 28% and 24%, respectively. After methotrexate, 23% of patients experienced delayed excretion, in 4 cases with nephrotoxicity.Conclusions:In patients over 40 years of age with primary high-grade osteosarcoma, an aggressive approach with chemotherapy and surgery can offer the probability of survival similar to that achieved in younger patients. Chemotherapy-related toxicity is significant and generally higher than that reported in younger cohorts of osteosarcoma patients treated with more intensive regimens. | ||
| 534 | |c 2017 | ||
| 700 | 1 | |a Egerer, Gerlinde |e VerfasserIn |0 (DE-588)105502168X |0 (DE-627)792516745 |0 (DE-576)167430882 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tumori journal |d Thousand Oaks, Calif. : Sage Publishing, 1947 |g 104(2018), 1, Seite 30-36 |h Online-Ressource |w (DE-627)523575432 |w (DE-600)2267832-3 |w (DE-576)347278078 |x 2038-2529 |7 nnas |a EURO-B.O.S.S. a European study on chemotherapy in bone-sarcoma patients aged over 40: outcome in primary high-grade osteosarcoma |
| 773 | 1 | 8 | |g volume:104 |g year:2018 |g number:1 |g pages:30-36 |g extent:7 |a EURO-B.O.S.S. a European study on chemotherapy in bone-sarcoma patients aged over 40: outcome in primary high-grade osteosarcoma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5301/tj.5000696 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180913 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 105502168X |a Egerer, Gerlinde |m 105502168X:Egerer, Gerlinde |d 910000 |d 910100 |e 910000PE105502168X |e 910100PE105502168X |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 999 | |a KXP-PPN1580944124 |e 3025489243 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"EURO-B.O.S.S.","title":"EURO-B.O.S.S.","subtitle":"a European study on chemotherapy in bone-sarcoma patients aged over 40: outcome in primary high-grade osteosarcoma"}],"person":[{"family":"Ferrari","given":"Stefano","display":"Ferrari, Stefano","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","display":"Egerer, Gerlinde","roleDisplay":"VerfasserIn","given":"Gerlinde","family":"Egerer"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Published online: December 5, 2017","Gesehen am 30.08.2019"],"recId":"1580944124","language":["eng"],"origin":[{"dateIssuedDisp":"2018","dateIssuedKey":"2018"}],"id":{"eki":["1580944124"],"doi":["10.5301/tj.5000696"]},"name":{"displayForm":["Stefano Ferrari, Stefan S. Bielack, Sigbjørn Smeland, Alessandra Longhi, Gerlinde Egerer, Kirsten Sundby Hall, Davide Donati, Matthias Kevric, Otte Brosjö, Alessandro Comandone, Mathias Werner, Odd Monge, Emanuela Palmerini, Wolfgang E. Berdel, Bodil Bjerkehagen, Anna Paioli, Sylvie Lorenzen, Mikael Eriksson, Marco Gambarotti, Per-Ulf Tunn, Nina L. Jebsen, Marilena Cesari, Thekla von Kalle, Virginia Ferraresi, Rudolf Schwarz, Rossella Bertulli, Anne-Katrin Kasparek, Giovanni Grignani, Fatime Krasniqi, Benjamin Sorg, Stefanie Hecker-Nolting, Piero Picci, Peter Reichardt"]},"physDesc":[{"extent":"7 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2038-2529"],"eki":["523575432"],"zdb":["2267832-3"]},"origin":[{"publisherPlace":"Thousand Oaks, Calif. ; Milano ; Roma ; Milano","publisher":"Sage Publishing ; Casa Ed. Ambrosiana ; Pensiero Scientifico Ed. ; Wichtig","dateIssuedKey":"1947","dateIssuedDisp":"1947-"}],"name":{"displayForm":["published in association with Italian Association of Medical Oncology (AIOM), Italian Association of Radiation Oncology (AIRO), Italian Cancer Society (SIC), Italian Society of Surgical Oncology (SICO), published on behalf of the Tumori National Institute of Milano"]},"titleAlt":[{"title":"a journal of experimental and clinical oncology"},{"title":"TJ"},{"title":"Tumori"}],"part":{"extent":"7","text":"104(2018), 1, Seite 30-36","volume":"104","pages":"30-36","issue":"1","year":"2018"},"pubHistory":["Nachgewiesen 33.1947 -"],"language":["ita","eng"],"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"Istituto nazionale per lo studio e la cura dei tumori"}],"recId":"523575432","disp":"EURO-B.O.S.S. a European study on chemotherapy in bone-sarcoma patients aged over 40: outcome in primary high-grade osteosarcomaTumori journal","note":["Gesehen am 01.04.2020"],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title_sort":"Tumori journal","subtitle":"TJ","title":"Tumori journal"}]}]} | ||
| SRT | |a FERRARISTEEUROBOSS2018 | ||